Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The report said the F.D.A.’s approval process for Aduhelm was [...]
Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trial
Preliminary results offer hope that gene therapy can protect people [...]
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The drug, lecanemab, made by Eisai and Biogen, also carried [...]
What A.L.S. and Alzheimer’s Drug Approvals Have in Common
Regulators must balance patient’s needs with their safety.
Alzheimer’s Drug Slows Cognitive Decline in Key Study
Biogen and Eisai reported the finding from a large late-stage [...]
Trial of New Alzheimer’s Drug Reports Disappointing Results
The drug, crenezumab, failed to prevent early symptoms or slow [...]
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm
The drug company will effectively give up on marketing Aduhelm, [...]
Scientists Question Data Behind an Experimental Alzheimer’s Drug
Studies linked to Cassava Sciences, once a stock market favorite, [...]
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Officials cited data showing the new Alzheimer’s drug has serious [...]
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug
The Alzheimer’s Association has pushed relentlessly to get broad access [...]